Notably, NFKBIA silencing is also found far more frequently in patients with NSCLC who lack EGFR mutations than in those with EGFR-mutant NSCLC, which suggests that such downstream activation of the PI3K/AKT pathway can bypass the need for mutations in upstream driver proteins during carcinogenesis [85]. Here, EGFR is linked to non-small cell lung carcinoma.